赛利司他(ATL-962)、利莫那班和赛尼可的研发与市场趋势  

Research and Development and Market Trends of Anti-obesity Drugs such as Cetilistat(ATL-962),Rimonabant and Xenical

作　　者：阎家麒[1] 高荣[1] 谢建平[1] 

机构地区：[1]泰州市今朝伟业精细化工有限公司,江苏泰州225327

出　　处：《化工时刊》2008年第2期72-73,共2页Chemical Industry Times

摘　　要：本文阐述了赛利司他、利莫那班和赛尼可3种新减肥药物的研发和市场趋势,同时对这3种减肥药物作了疗效比较,并对各种药物的优缺点进行了分析。赛利司他和利莫那班蕴藏着巨大商机,尤其是脂肪酶抑制剂赛利司他。The research and development of three new anti-obesity drugs such as Cetilitat（ATL-962）, Rimonabant and Xenical and their current market trends were presented. Meanwhile, the three drugs effects in administration and the advantages and disadvantages of each were analyzed. Cetilitat （ATL-962）, Rimonabant had the potential to greatly enhance the market opportunity for lipase inhibitors and thus the potential for Cetilistat.

关 键 词：赛利司他 利莫那班赛尼可 减肥药物 

分 类 号：F416.72[经济管理—产业经济]